A federal jury has ordered Wyeth Pharmaceuticals and Upjohn to pay more than $27 million to Donna Scroggin of Little Rock, AR. Scroggin sued the companies in 2004 after developing breast cancer following hormone replacement …

Severe psychological stress may play a role in the development of breast cancer, according to a study conducted at Queen’s University. Biochemist Christopher Mueller led the study and found that the stress hormone hydrocortisone may …

Researchers at Massachusetts General Hospital report good news for the drug, Femara (letrozole), used to prevent the recurrence of some forms of breast cancer, even when started long after the initial course of treatment has …

Experts at London’s Guy’s Hospital reviewed 27 years worth of studies and concluded that anti-inflammatory drugs like aspirin may reduce breast cancer by up to 20 percent.
The studies reviewed included 11 studies of women with …

A new study published in the March issue of Cancer Epidemiology, Biomarkers and Prevention demonstrates that women who have a recurrence of breast cancer have almost twice as much estrogen in their blood than those …

The Journal of the National Cancer Institute in Canada has just published findings showing that women who are diagnosed with breast cancer experience a drop in wages during their first year of treatment of almost …

Hormone therapy is commonly used to help treat women with menopause. However, this therapy can increase their risk of having abnormal mammograms and breast biopsies and may decrease the effectiveness of both methods for detecting …

Patsy Bates, a 52-year-old breast cancer patient, just learned of a court order that awards her $9 million dollars in damages after her healthcare provider, Health Net Inc., one of California’s largest private medical insurance …

Oncologists and women suffering from breast cancer may have yet another tool in their fight against the disease. Genentech, Inc. has announced this week that the FDA will be granting an accelerated approval for Avastin …

A study released this week by the American Cancer Society outlined disturbing differences in survival rates among insured versus uninsured patients. The study, which appears in the March issue of The Lancet Oncology, is the …